Peritoneal metastasis from colorectal cancer

New treatment strategy for peritoneal metastasis for colorectal cancer

  • Whilst treatment outcomes for pseudomyxoma peritonei (PMP) are excellent, peritoneal metastasis, otherwise called peritoneal carcinomatosis / dissemination, from colorectal cancer (PMCRC), exhibits more aggressive biological behaviour and is generally considered a fatal condition that is not amenable to surgery.
  • Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is feasible in a subset of patients with either limited disease or visceral sparing and there is emerging evidence for CRS and HIPEC in selected patients with PMCRC.
  • Our hospital provides an innovative multidisciplinary treatment using new chemotherapeutic agents in neo-adjuvant and adjuvant settings in combination with CRS+HIPEC.